Clinical Trial Update: A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating the safety, efficacy, and pharmacokinetics of YL201 in metastatic castration-resistant prostate cancer is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• YL201

Snippet

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 2 | Status: RECRUITING